A detailed history of Skopos Labs, Inc. transactions in Myriad Genetics Inc stock. As of the latest transaction made, Skopos Labs, Inc. holds 41,155 shares of MYGN stock, worth $276,150. This represents 0.04% of its overall portfolio holdings.

Number of Shares
41,155
Previous 35,045 17.43%
Holding current value
$276,150
Previous $253,000 17.39%
% of portfolio
0.04%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$3.84 - $7.84 $23,462 - $47,902
6,110 Added 17.43%
41,155 $297,000
Q3 2025

Nov 14, 2025

SELL
$3.84 - $7.84 $23,462 - $47,902
-6,110 Reduced 14.85%
35,045 $253,000
Q2 2025

Aug 14, 2025

BUY
$3.84 - $8.84 $157,416 - $362,386
40,994 Added 25462.11%
41,155 $218,000
Q1 2025

May 13, 2025

SELL
$8.87 - $14.98 $2,669 - $4,508
-301 Reduced 65.15%
161 $1,000
Q4 2024

Jan 15, 2025

BUY
$13.17 - $27.03 $6,084 - $12,487
462 New
462 $6,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $541M
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Skopos Labs, Inc. Portfolio

Follow Skopos Labs, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skopos Labs, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Skopos Labs, Inc. with notifications on news.